Evidence for Using Doxazosin in the Treatment of Posttraumatic Stress Disorder

被引:16
|
作者
Smith, Cherish [1 ]
Koola, Maju Mathew [2 ,3 ]
机构
[1] Xavier Univ, Sch Med, Cincinnati, OH 45207 USA
[2] George Washington Univ, Sch Med, Dept Psychiat & Behav Sci, Washington, DC 20052 USA
[3] Sheppard Pratt Hlth Syst, Clin Res Program, 6501 N Charles St, Baltimore, MD 21204 USA
关键词
D O I
10.3928/00485713-20160728-01
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
There is evidence that doxazosin is effective in the treatment of posttraumatic stress disorder (PTSD). Doxazosin is a "me-too" drug of prazosin. Doxazosin has an improved absorption profile and this likely minimizes the risk for unintended adverse hypotensive effects. The availability of doxazosin in the gastrointestinal therapeutic system (GITS) form permits a higher initial daily dose (4 mg/day) while avoiding significant first-dose side effects. The treatment of PTSD with prazosin has several disadvantages due to its short duration of action (6-8 hours), which results in multiple doses being required. Prazosin may wear off and this may lead to nightmares in the latter half of the sleep. Doxazosin has significant advantages over prazosin in clinical practice because it has a long half-life and requires only once-daily dosing. This may lead to better adherence and greater effectiveness in the treatment of PTSD.
引用
收藏
页码:553 / U68
页数:3
相关论文
共 50 条
  • [1] Doxazosin Treatment for Posttraumatic Stress Disorder
    De Jong, Joop
    Wauben, Prudence
    Huijbrechts, Irma
    Oolders, Hans
    Haffmans, Judith
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2010, 30 (01) : 84 - 85
  • [2] Treatment of posttraumatic stress disorder
    Gerlach, A
    [J]. ZEITSCHRIFT FUR KLINISCHE PSYCHOLOGIE-FORSCHUNG UND PRAXIS, 1999, 28 (03): : 220 - 221
  • [3] Treatment for posttraumatic stress disorder
    Cyr, M
    Farrar, MK
    [J]. ANNALS OF PHARMACOTHERAPY, 2000, 34 (03) : 366 - 376
  • [5] Posttraumatic Stress Disorder: Overview of Evidence-Based Assessment and Treatment
    Lancaster, Cynthia L.
    Teeters, Jenni B.
    Gros, Daniel F.
    Back, Sudie E.
    [J]. JOURNAL OF CLINICAL MEDICINE, 2016, 5 (11)
  • [6] The Evidence for Present-Centered Therapy as a Treatment for Posttraumatic Stress Disorder
    Frost, Nickolas D.
    Laska, Kevin M.
    Wampold, Bruce E.
    [J]. JOURNAL OF TRAUMATIC STRESS, 2014, 27 (01) : 1 - 8
  • [7] Translational evidence for a role of endocannabinoids in the etiology and treatment of posttraumatic stress disorder
    Neumeister, Alexander
    Seidel, Jordan
    Ragen, Benjamin J.
    Pietrzak, Robert H.
    [J]. PSYCHONEUROENDOCRINOLOGY, 2015, 51 : 577 - 584
  • [8] Treatment of posttraumatic stress disorder with tiagabine
    Berigan, T
    [J]. CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2002, 47 (08): : 788 - 788
  • [9] Treatment of posttraumatic stress disorder with nefazodone
    Davidson, JRT
    Weisler, RH
    Malik, ML
    Connor, KM
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 1998, 13 (03) : 111 - 113
  • [10] Pharmacological treatment of posttraumatic stress disorder
    Roepke, Stefan
    Schellong, Julia
    Bergemann, Niels
    Frommberger, Ulrich
    Schmidt, Ulrike
    [J]. NERVENARZT, 2024, 95 (07): : 622 - 629